Halozyme Therapeutics Inc. Common Stock vs Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) trades at $25.13 (market cap $156.97B). The key difference: Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) is far larger — about 12.5× Halozyme Therapeutics Inc. Common Stock's market cap, and Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) pays a 2.34% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) for 1 Days on average.
| HALO | SMFG | |
|---|---|---|
Market Cap | $12.58B | $156.97B |
Volume | 2,179,278 | 1,237,125 |
Sector | Health | Financials |
52-Week High | $115.22 | $27.56 |
52-Week Low | $61.63 | $15.20 |
Typical Hold Time | 1 Days | 1 Days |
Enterprise Value | $14.49B | $12.48T |
Dividend Yield | — | 2.34% |
Trailing returns across standard periods
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →Sumitomo Mitsui Financial Group is a Japanese financial services company with banking, securities, leasing, and asset management businesses. It serves retail, corporate, and institutional clients.
Read more on SMFG →